Single‐center, assessor‐blind study to evaluate the efficacy and safety of DA‐5520 topical gel in patients with acne scars: A pilot study

Abstract Background Unlike various topical treatment options for acne vulgaris, options for acne scars mostly involve invasive interventions. So far, only a few clinical trials have investigated the effects of topical treatment for acne scars. Objectives We evaluated the safety and efficacy of DA‐5520, a recently developed topical gel for the treatment of different types of acne scars. Methods A 12‐week prospective, randomized, active‐controlled, evaluator‐blind, single‐center study involving 36 participants with acne scars was performed. Participants were randomized into four different groups at a 1:1:1:1 ratio: laser resurfacing with DA‐5520 application (test 1); laser resurfacing without DA‐5520 application (control 1); comedone extraction with DA‐5520 application (test 2); and comedone extraction without DA‐5520 application (control 2). For 12 weeks, participants in the two test groups applied DA‐5520 twice daily, while participants in the control groups applied moisturizers alone. Participants in the test 1 and control 1 groups received a single session of laser resurfacing at visit 1 (week 0). All participants were followed up at 1, 4, 8, and 12 weeks, and objective scar evaluation using the échelle d’évaluation clinique des cicatrices d'acné (ECCA) score was performed at each visit. Results Clinical improvement of acne scars, confirmed by the ECCA grading scale (1 for atrophic scar and 2 for hypertrophic scar), was observed after using DA‐5520 when combined with laser resurfacing or individually, and no associated adverse reactions were noted. Conclusions Preliminary results of this study revealed that DA‐5520 may be a promising new formulation for treating all type of acne scars.